News Spero snaps up Innovent immunology drug in strategic pivot Spero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R&D.
News Digital check-ins improve cancer care and reduce inequality A study has shown that, for people living with advanced cancer, a weekly remote check-in with the care team can have a significant impact on outcomes.
News AstraZeneca adds another Chinese asset, from Dizal AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.
News First trial of Bundibugyo Ebola vaccine starts in UK Oxford University has launched what it says is the world's first phase I trial of a vaccine specifically designed to protect against Bundibugyo Ebola.
News FDA clears at-home start dose for Alzheimer's drug Leqembi The FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.
News Major trial launched to explore GLP-1 benefit in dementia A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.